Once-daily beta-agonist for COPD earns FDA panel support
January 30, 2013|Pulmonary Health Hub
Author and Disclosure Information
AT A MEETING OF THE FDA'S PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE
The LABAs currently approved by the FDA are salmeterol, formoterol, and indacaterol.
The FDA usually follows the recommendations of its advisory panels, which are not binding. Panelists have been cleared of potential conflicts of interest related to the topic of the meeting, although a panelist may be given a waiver, but none were granted at this meeting.
